A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers

Trial Profile

A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Enoblituzumab (Primary) ; Ipilimumab
  • Indications Breast cancer; Colon cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Soft tissue sarcoma; Squamous cell cancer; Thyroid cancer; Urogenital cancer
  • Focus Adverse reactions
  • Sponsors MacroGenics
  • Most Recent Events

    • 11 Apr 2017 Planned number of patients changed from 84 to 59.
    • 17 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
    • 12 Mar 2015 Status changed from planning to not yet recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top